For years, you’ve been replacing your patient’s testosterone. Maybe it’s time to consider replacing how it’s delivered. While there have been frequent, and prominent, new products developed for treating hypogonadism in the last 20 years, one particular type of option has been scarce – and it may be the one that patients want and/or prefer. […]
A federal appeals court threw out an order requiring AbbVie Inc. and a partner to disgorge $448 million in profit for trying to keep generic versions of the blockbuster testosterone replacement drug AndroGel off the market.
A U.S. judge overturned a $140.1 million verdict against AbbVie Inc. in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack.
A U.S. judge found that pharmaceutical company AbbVie Inc. used sham litigation to illegally prevent generic versions of the testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.
A federal jury found AbbVie not liable in a lawsuit by an Arizona man who claimed he suffered a pulmonary embolism due to using the company’s testosterone replacement medication AndroGel.
Here are five companies looking at possible drug approvals in January 2018.
A judge overturned a $150 million verdict against AbbVie, the first resulting from lawsuits claiming the company fraudulently misrepresented the risks of AndroGel.
The U.S. FDA identified unnamed deficiencies in Antares Pharma’s NDA for Xyosted that halted discussion of labeling and postmarketing requirements.
A federal jury in Chicago found AbbVie Inc. fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.